Straits Times Index
3,306.02 +6.02 (+0.18%) Nikkei
38,596.47 -36.55 (-0.09%) Hang Seng
18,028.52 -306.80 (-1.67%) FTSE 100
8,237.72 -34.74 (-0.42%) Bitcoin USD
64,301.62 -745.84 (-1.15%) CMC Crypto 200
1,330.89 -29.43 (-2.16%)
Amgen Inc. (AMGN.MX)
| Previous close | 5,680.85 |
| Open | 5,680.85 |
| Bid | 4,718.00 x 1300 |
| Ask | 6,500.00 x 100000 |
| Day's range | 5,680.85 - 5,680.85 |
| 52-week range | 3,800.00 - 5,680.85 |
| Volume | |
| Avg. volume | 99 |
| Market cap | 3.065T |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | 44.05 |
| EPS (TTM) | 128.96 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | 161.04 (2.83%) |
| Ex-dividend date | 16 May 2024 |
| 1y target est | N/A |
- Yahoo Finance Video
The 30-stock secret: ‘Don’t fight Papa Dow’
JC Parets, founder and chief strategist at All Star Charts, explains why fighting the Dow Breadth is futile and how embracing the approach can simplify your market analysis significantly. He spoke with Yahoo Finance’s Jared Blikre and Sydnee Fried on "Stocks in Translation." Listen to the full episode here, or wherever you get your podcasts. This post was written by Jared Blikre
PR NewswireFDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE
Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved BLINCYTO® (blinatumomab) for the treatment of adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of measurable residual disease (MRD) status.
- PR Newswire
AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024
Amgen (NASDAQ:AMGN) today announced the presentation of data across its diverse portfolio and pipeline at the European Alliance of Associations for Rheumatology's (EULAR) 2024 Congress, June 12-15 in Vienna. The 27 abstracts from Amgen-sponsored and partner-led studies demonstrate Amgen's commitment to improving the lives of patients living with inflammatory and rheumatic disease through the development of novel medicines.
